Piotr Wysocki: How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?

Piotr Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital, recently shared on LinkedIn:

“I want to share with you my personal view on the optimal utilisation of currently available treatments for advanced HR+/HER2- breast cancer. The review published online in JCO Oncology Practice summarizes the available data on the efficacy and safety of various therapeutic strategies in relationship to current reimbursement limitations in Poland and many other EU countries (lack of reimbursement of everolimus and unavailability of capivasertib). You can download the whole paper here.”

Source: Piotr Wysocki/LinkedIn